Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Vasc Endovasc Surg ; 67(5): 811-817, 2024 May.
Article in English | MEDLINE | ID: mdl-38311050

ABSTRACT

OBJECTIVE: Superficial venous incompetence (SVI) is a common disease that causes significant quality of life (QoL) impairment. There is a need for more health economic evaluations of SVI treatment. The aim of this study was to perform a cost effectiveness analysis in patients with great saphenous vein (GSV) incompetence comparing radiofrequency ablation (RFA), high ligation and stripping (HL/S), and no treatment or conservative treatment with one year follow up. METHODS: Randomised controlled trial economic analysis from an ongoing trial; 143 patients (156 limbs) with GSV incompetence (CEAP clinical class 2 - 6) were included. Treatment was performed with RFA or HL/S. Follow up was performed up to one year using duplex ultrasound, revised venous clinical severity score (r-VCSS), Aberdeen Varicose Vein Questionnaire (AVVQ), and EuroQol-5D-3L (EQ-5D-3L). RESULTS: Seventy-eight limbs were treated with RFA and HL/S respectively. No treatment or conservative treatment was assumed to have zero in treatment cost and no treatment benefit. In the RFA group, one limb had reflux in the GSV after one month and three limbs after one year. In HL/S, two limbs had remaining reflux in the treated area at one month and one year. Both disease severity (r-VCSS, p = .004) and QoL (AVVQ, p = .021 and EQ-5D-3L, p = .028) were significantly improved over time. The QALY gain was 0.21 for RFA and 0.17 for HL/S. The cost per patient was calculated as €1 292 for RFA and €2 303 for HL/S. The cost per QALY (compared with no treatment or conservative treatment) was €6 155 for RFA and €13 549 for HL/S. With added cost for days absent from work the cost per QALY was €7 358 for RFA and €24 197 for HL/S. The cost per QALY for both methods was well below the threshold suggested by Swedish National Board of Health. CONCLUSION: RFA is more cost effective than HL/S and no treatment or conservative treatment at one year follow up.


Subject(s)
Cost-Benefit Analysis , Quality of Life , Radiofrequency Ablation , Saphenous Vein , Venous Insufficiency , Humans , Ligation/economics , Saphenous Vein/surgery , Saphenous Vein/diagnostic imaging , Venous Insufficiency/surgery , Venous Insufficiency/economics , Venous Insufficiency/diagnostic imaging , Female , Male , Middle Aged , Treatment Outcome , Radiofrequency Ablation/economics , Radiofrequency Ablation/adverse effects , Quality-Adjusted Life Years , Time Factors , Vascular Surgical Procedures/economics , Vascular Surgical Procedures/adverse effects , Vascular Surgical Procedures/methods , Aged , Catheter Ablation/economics , Catheter Ablation/adverse effects , Catheter Ablation/methods , Adult , Health Care Costs , Varicose Veins/surgery , Varicose Veins/economics , Varicose Veins/diagnostic imaging , Cost-Effectiveness Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...